CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM083118
Első szerző:Bor Renáta
Cím:Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease : a nationwide Hungarian cohort study / Bor Renáta, Fábián Anna, Matuz Mária, Szepes Zoltán, Farkas Klaudia, Miheller Pál, Szamosi Tamás, Vincze Áron, Rutka Mariann, Szántó Kata, Bálint Anita, Nagy Ferenc, Milassin Ágnes, Tóth Tibor, Zsigmond Ferenc, Bajor Judit, Müllner Katalin, Lakner Lilla, Papp Mária, Salamon Ágnes, Horváth Gábor, Sarang Krisztina, Schäfer Eszter, Sarlós Patrícia, Palatka Károly, Molnár Tamás
Dátum:2020
ISSN:1471-2598
Megjegyzések:ABSTRACT Background: GEMINI trials demonstrated the therapeutic efficacy of vedolizumab (VDZ) in Crohn's disease (CD) and ulcerative colitis (UC). Research design and methods: Aim of this study was to determine the real-life effectiveness of VDZ on endoscopic healing in the Hungarian nationwide cohort of inflammatory bowel disease (IBD) patients based on the changes on clinical and endoscopic scores. Every adult IBD patient in the country (121 UC and 83 CD) who completed the short-term VDZ therapy was enrolled, of which 72 UC and 52 CD patients could complete the long-term therapy. Results: The rates of endoscopic healing were substantially higher in UC compared with CD patients during the short- and long-term therapy (52.9% vs. 21.7%, p < 0.0001, and 51.4% vs. 21.2%, p = 0.015, respectively). In CD, the rate of endoscopic healing was lower at week 14 compared with week 22 (14.5% vs. 37.0%, p = 0.026). Prior anti-TNF-? therapy (88.73%) was not associated with a significant decrease in therapeutic response. The average disease duration was significantly lower in CD patients achieving endoscopic healing at week 52 (11.75 vs. 5.27 years, p = 0.007). Conclusions: VDZ therapy is an effective therapeutic option in anti-TNF-? refractory IBD. However, the endoscopic healing rate was substantially lower and showed a significant delay in CD compared with UC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Crohn's disease
ulcerative colitis
VDZ
vedolizumab
IBD
Megjelenés:Expert Opinion On Biological Therapy. - 20 : 2 (2020), p. 205-213. -
További szerzők:Fábián Anna Matuz Mária Szepes Zoltán Farkas Klaudia Miheller Pál Szamosi Tamás Vincze Áron Rutka Mariann Szántó Kata Bálint Anita Nagy Ferenc (orvos Szeged) Milassin Ágnes Tóth Tibor Zsigmond Ferenc Bajor Judit Müllner Katalin (Budapest) Lakner Lilla Papp Mária (1975-) (belgyógyász, gasztroenterológus) Salamon Ágnes (orvos Szekszárd) Horváth Gábor (orvos Miskolc) Sarang Krisztina Schafer Eszter Sarlós Patrícia Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Molnár Tamás (orvos Szeged)
Pályázati támogatás:EFOP-3.6.2-16-2017-00006
EFOP
119809
OTKA
125377
OTKA
129266
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM010927
Első szerző:Szamosi Tamás
Cím:Early azathioprine/biological therapy is associated with decreased risk for surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis / Tamas Szamosi, Janos Banai, Laszlo Lakatos, Zsofia Czegledi, Gyula David, Ferenc Zsigmond, Tunde Pandur, Zsuzsanna Erdelyi, Orsolya Gemela, Maria Papp, Janos Papp, Peter Laszlo Lakatos
Dátum:2010
ISSN:0954-691X (Print)
Megjegyzések:Smoking may alter the natural course of Crohn's disease (CD). Smokers are more likely to develop complications, relapses and have a greater risk for surgery. In contrast, in ulcerative colitis (UC), smoking might improve the disease course. Our aim was to assess the combined effect of disease phenotype, smoking, and immunomodulator [azathioprine (AZA), AZA/biological] treatment on the risk of intestinal resection/reoperation in CD and colectomy in UC. PATIENTS/METHODS: Six hundred and eighty-one inflammatory bowel disease patients were analyzed (CD: 340, male/female: 155/185, duration: 9.4+/-7.5 years; UC: 341, male/female: 174/164, duration: 11.5+/-9.7 years). Patients were interviewed on their smoking habits at the time of diagnosis and during the regular follow-up visits. Medical records were retrospectively analyzed. RESULTS: Smoking was present in 45.5% in CD and 15.8% in UC. CD patients who underwent at least one bowel resection comprised 46.5%. In an univariate analysis, disease location, behavior, AZA, or AZA/biological use before surgery [odds ratio (OR): 0.26 and 0.22, P<0.001] and smoking (OR: 1.61, P = 0.03) were associated with risk for first surgery. Smoking, AZA, or AZA/biological (P<0.001) use before first surgery and disease behavior were independently associated with risk for surgery in a proportional Cox-regression analysis. Perianal disease (OR: 3.2, P = 0.001) and frequent relapses (OR: 4.8, P<0.001) but not smoking, AZA, or AZA/biological use after first surgery were predictive for reoperation. In UC, the rate of colectomy was 5.6%. Disease location (P = 0.001) and smoking status (P = 0.02) were independently associated with risk for colectomy in a proportional Cox-regression analysis. CONCLUSION: Our data suggest that early AZA/biological therapy reduces the risk for first operation but not reoperation in CD, in both smokers and nonsmokers. In contrast, smoking was associated with a decreased need for colectomy in UC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:European Journal of Gastroenterology and Hepatology 22 : 7 (2010), p. 872-879. -
További szerzők:Banai János Lakatos László (orvos Budapest) Czeglédi Zsófia Dávid Gyula Zsigmond Ferenc Pandúr Tünde Erdélyi Zsuzsanna Gemela Orsolya Papp Mária (1975-) (belgyógyász, gasztroenterológus) Papp János (orvos Veszprém) Lakatos Péter (Semmelweis Egyetem)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1